Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

New data examines effect of inhaled corticosteroids (ICS) on survival in patients with COPD

07.11.2002


New data examines effect of inhaled corticosteroids (ICS) on survival in patients with chronic obstructive pulmonary disease (COPD)

The findings of a retrospective database study examining the effect of inhaled corticosteroids (ICS) on survival in COPD patients1 were presented today at the American College of Chest Physicians CHEST 2002 Annual Conference in San Diego.

The investigators identified male and female patients, ages 40 and older, who were enrolled in the Lovelace and Kaiser Permanente-Georgia health plans during 1995 to 2000 and who had a diagnosis of COPD. In total, 1,685 patients were identified: the ’exposed groups’ consisted of patients who had 90 days or more use of ICS (n= 786), ICS plus salmeterol (n=332) or salmeterol without ICS (n=170); the reference, or ’unexposed,’ group (n=397) were patients who had not used ICS or a long-acting beta2-agonist but had been exposed to another respiratory drug for 90 days or more.



During the study period, 28 percent of patients in the unexposed group died compared to 14 percent of patients who had been exposed to ICS and/or salmeterol. In a statistical model that controlled for age, sex, comorbid conditions, COPD severity, and asthma status and severity, exposure to either ICS (Hazard Ratio [HR] 0.59, 95% Confidence Interval [CI]: 0.46, 0.78) or salmeterol (Hazard Ratio [HR] 0.55, 95% Confidence Interval [CI]: 0.34, 0.89) were associated with a decreased risk of death. In addition, exposure to ICS plus salmeterol also reduced the risk of death (HR 0.34, 95% CI: 0.21, 0.56). In a sensitivity analysis including only those COPD patients without a history of asthma (n=840), the reduction in risk of death associated with the use of ICS plus salmeterol remained significant (HR 0.35, 95% CI: 0.17, 0.71). Use of inhaled corticosteroids was associated with longer survival in COPD patients, independent of an asthma diagnosis, age, gender, or COPD severity.

According to the CDC, approximately 24 million Americans have evidence of impaired lung function consistent with a diagnosis of COPD, the fourth leading cause of death in the US. 2 In 2000, there were 119,052 deaths from COPD. 2

COPD is a multi-component disease that includes airway inflammation, bronchoconstriction and structural changes that result in airflow obstruction. These components contribute to complex changes in lung function, symptoms and exacerbations, which affect health status and ultimately survival.

No drug has been prospectively shown to reduce mortality in COPD. It is important to note that no inhaled corticosteroid alone, or combined with a long-acting bronchodilator, is currently approved for the treatment of COPD in the US.

Serevent DiskusÒ (salmeterol inhalation powder) should be used with caution in patients with cardiovascular disorders, especially coronary insufficiency, cardiac arrthymias, and hypertension, and in patients with convulsive disorders or thytotoxicosis. Some patients may experience an increase in blood pressure or heart rate. Salmeterol should be administered with extreme caution to patients being treated with monoamine oxidase inhibitors or tricyclic antidepressants.


Contact Robin Gaitens at 919-483-2839 for complete prescribing information for Serevent Diskus.

Sources

1. Mapel D, Roblin D, Hurley J, Davis KJ, Schreiner R, Roberts M, Frost F. Survival of COPD patients exposed to inhaled corticosteroids. Chest 2002;122(4 Suppl):74S.

2. "Chronic Obstructive Pulmonary Disease Surveillance – United States, 1971-2000," Morbidity and Mortality Weekly Report, vol. 51; No. SS-6; August 2, 2002.


Robin Gaitens | EurekAlert!

More articles from Health and Medicine:

nachricht Hot cars can hit deadly temperatures in as little as one hour
24.05.2018 | Arizona State University

nachricht 3D images of cancer cells in the body: Medical physicists from Halle present new method
16.05.2018 | Martin-Luther-Universität Halle-Wittenberg

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Powerful IT security for the car of the future – research alliance develops new approaches

The more electronics steer, accelerate and brake cars, the more important it is to protect them against cyber-attacks. That is why 15 partners from industry and academia will work together over the next three years on new approaches to IT security in self-driving cars. The joint project goes by the name Security For Connected, Autonomous Cars (SecForCARs) and has funding of €7.2 million from the German Federal Ministry of Education and Research. Infineon is leading the project.

Vehicles already offer diverse communication interfaces and more and more automated functions, such as distance and lane-keeping assist systems. At the same...

Im Focus: Molecular switch will facilitate the development of pioneering electro-optical devices

A research team led by physicists at the Technical University of Munich (TUM) has developed molecular nanoswitches that can be toggled between two structurally different states using an applied voltage. They can serve as the basis for a pioneering class of devices that could replace silicon-based components with organic molecules.

The development of new electronic technologies drives the incessant reduction of functional component sizes. In the context of an international collaborative...

Im Focus: LZH showcases laser material processing of tomorrow at the LASYS 2018

At the LASYS 2018, from June 5th to 7th, the Laser Zentrum Hannover e.V. (LZH) will be showcasing processes for the laser material processing of tomorrow in hall 4 at stand 4E75. With blown bomb shells the LZH will present first results of a research project on civil security.

At this year's LASYS, the LZH will exhibit light-based processes such as cutting, welding, ablation and structuring as well as additive manufacturing for...

Im Focus: Self-illuminating pixels for a new display generation

There are videos on the internet that can make one marvel at technology. For example, a smartphone is casually bent around the arm or a thin-film display is rolled in all directions and with almost every diameter. From the user's point of view, this looks fantastic. From a professional point of view, however, the question arises: Is that already possible?

At Display Week 2018, scientists from the Fraunhofer Institute for Applied Polymer Research IAP will be demonstrating today’s technological possibilities and...

Im Focus: Explanation for puzzling quantum oscillations has been found

So-called quantum many-body scars allow quantum systems to stay out of equilibrium much longer, explaining experiment | Study published in Nature Physics

Recently, researchers from Harvard and MIT succeeded in trapping a record 53 atoms and individually controlling their quantum state, realizing what is called a...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

In focus: Climate adapted plants

25.05.2018 | Event News

Save the date: Forum European Neuroscience – 07-11 July 2018 in Berlin, Germany

02.05.2018 | Event News

Invitation to the upcoming "Current Topics in Bioinformatics: Big Data in Genomics and Medicine"

13.04.2018 | Event News

 
Latest News

In focus: Climate adapted plants

25.05.2018 | Event News

Flow probes from the 3D printer

25.05.2018 | Machine Engineering

Less is more? Gene switch for healthy aging found

25.05.2018 | Life Sciences

VideoLinks
Science & Research
Overview of more VideoLinks >>>